Despite his unceremonious exit from WWE in 2001, former WCW star Buff Bagwell expressed a desire to be welcomed back to WWE ...

Marcus Freeman has done a tremendous job in Year 3 of his tenure at Notre Dame. The former Ohio State Buckeyes linebacker ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating today.Stay Ahead of the ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn't go as far as the takeover that some market commentators have been predicting.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination ...

Investing.com -- Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/2 clinical trial. The ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.